<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-05161R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0003662</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cell Biology</subject><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Cardiovascular Disorders/Coronary Artery Disease</subject></subj-group></article-categories><title-group><article-title>Male-Specific Association between a &#x003b3;-Secretase Polymorphism and Premature Coronary Atherosclerosis</article-title><alt-title alt-title-type="running-head">APH1B and Atherosclerosis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van Loo</surname><given-names>Karen M. J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dejaegere</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Zweeden</surname><given-names>Martine</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Schijndel</surname><given-names>Jessica E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wijmenga</surname><given-names>Cisca</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Trip</surname><given-names>Mieke D.</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Martens</surname><given-names>Gerard J. M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Molecular Animal Physiology, Radboud University Nijmegen, Donders Institute for Brain, Cognition and Behaviour and Nijmegen Centre for Molecular Life Sciences (NCMLS), Nijmegen, The Netherlands</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Center for Human Genetics, KULeuven, Leuven, Belgium</addr-line></aff><aff id="aff4"><label>4</label><addr-line>The Complex Genetics Section, Department of Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Department of Genetics, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Toland</surname><given-names>Amanda Ewart</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Ohio State University Medical Center, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>g.martens@ncmls.ru.nl</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: KMJvL TD GJMM. Performed the experiments: KMJvL TD MvZ JEvS. Analyzed the data: KMJvL TD MvZ JEvS MDT GJMM. Contributed reagents/materials/analysis tools: CW MDT. Wrote the paper: KMJvL TD MvZ JEvS CW MDT GJMM.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2008</year></pub-date><volume>3</volume><issue>11</issue><elocation-id>e3662</elocation-id><history><date date-type="received"><day>19</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>17</day><month>10</month><year>2008</year></date></history><copyright-statement>van Loo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Background</title><p>Atherosclerosis is a common multifactorial disease resulting from an interaction between susceptibility genes and environmental factors. The causative genes that contribute to atherosclerosis are elusive. Based on recent findings with a Wistar rat model, we speculated that the &#x003b3;-secretase pathway may be associated with atherosclerosis.</p></sec><sec><title>Methodology/Principal Findings</title><p>We have tested for association of premature coronary atherosclerosis with a non-synonymous single-nucleotide polymorphism (SNP) in the &#x003b3;-secretase component APH1B (Phe217Leu; rs1047552), a SNP previously linked to Alzheimer's disease. Analysis of a Dutch Caucasian cohort (780 cases; 1414 controls) showed a higher prevalence of the risk allele in the patients (odds ratio (OR)&#x0200a;&#x0003d;&#x0200a;1.35), albeit not statistically different from the control population. Intriguingly, after gender stratification, the difference was significant in males (OR&#x0200a;&#x0003d;&#x0200a;1.63; p&#x0200a;&#x0003d;&#x0200a;0.033), but not in females (OR&#x0200a;&#x0003d;&#x0200a;0.50; p&#x0200a;&#x0003d;&#x0200a;0.20). Since Phe217Leu-mutated APH1B showed reduced &#x003b3;-secretase activity in mouse embryonic fibroblasts, the genetic variation is likely functional.</p></sec><sec><title>Conclusion/Significance</title><p>We conclude that, in a male-specific manner, disturbed &#x003b3;-secretase signalling may play a role in the susceptibility for premature coronary atherosclerosis.</p></sec></abstract><counts><page-count count="6"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Atherosclerosis is the basis of coronary artery disease and thought to be a multifactorial disease caused by susceptibility genes that act in concert with environmental factors. A number of susceptibility genes have been identified (e.g. apolipoprotein E (<italic>APOE</italic>) <xref ref-type="bibr" rid="pone.0003662-Horejsi1">&#x0005b;1&#x0005d;</xref>, low density lipoprotein receptor <xref ref-type="bibr" rid="pone.0003662-Salazar1">&#x0005b;2&#x0005d;</xref> and methylenetetrahydrofolate reductase <xref ref-type="bibr" rid="pone.0003662-Morita1">&#x0005b;3&#x0005d;</xref>), but the signalling pathways responsible for vascular cell pathology are elusive. Interestingly, Wistar rats that display a high susceptibility for the dopamine receptor agonist apomorphine, the so-called apomorphine-susceptible (APO-SUS) rats <xref ref-type="bibr" rid="pone.0003662-Cools1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0003662-Ellenbroek1">&#x0005b;5&#x0005d;</xref>, show an impaired vasorelaxation to adrenergic stimuli when compared with their phenotypic counterparts APO-UNSUS rats <xref ref-type="bibr" rid="pone.0003662-Riksen1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0003662-Smits1">&#x0005b;7&#x0005d;</xref>. Impaired vasorelaxation is associated with an increased risk for the development of hypertension and vascular diseases such as atherosclerosis <xref ref-type="bibr" rid="pone.0003662-Hadi1">&#x0005b;8&#x0005d;</xref>. We recently identified a gene-dosage imbalance of the &#x003b3;-secretase component Aph1b as the molecular-genetic basis of the difference between the APO-SUS and -UNSUS rats <xref ref-type="bibr" rid="pone.0003662-Coolen1">&#x0005b;9&#x0005d;</xref>. The &#x003b3;-secretase enzyme complex cleaves many type I transmembrane proteins, including the amyloid-&#x003b2; (A&#x003b2;) precursor protein APP (known to be involved in neuronal amyloid plaque formation in Alzheimer's disease &#x0005b;AD&#x0005d;), NOTCH1-4, neuregulin, low-density lipoprotein receptor related protein (LRP1, 2 and 8) and N-cadherin <xref ref-type="bibr" rid="pone.0003662-Kopan1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0003662-Koo1">&#x0005b;11&#x0005d;</xref>.</p><p>In view of the above findings, we hypothesize that the &#x003b3;-secretase pathway may be linked to atherosclerosis. Increasing evidence suggests a link between altered vascular homeostasis, as seen in atherosclerosis, and the neurodegenerative disease AD. Apart from a partially overlapping epidemiology and an altered cholesterol homeostasis, atherosclerosis and AD have also been found to share genetic risk factors, including <italic>APOE</italic> and <italic>LRP1</italic><xref ref-type="bibr" rid="pone.0003662-Horejsi1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0003662-Rubinsztein1">&#x0005b;12&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0003662-Kang1">&#x0005b;14&#x0005d;</xref>. Since the rare non-synonymous single-nucleotide polymorphism (SNP) Phe217Leu (rs1047552; T&#x0003e;G) in the human <italic>APH1B</italic> gene has recently been found to be associated with AD <xref ref-type="bibr" rid="pone.0003662-Poli1">&#x0005b;15&#x0005d;</xref>, we have now tested whether this SNP is also associated with premature coronary atherosclerosis.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Male-specific association of <italic>APH1B</italic> Phe217Leu with premature coronary atherosclerosis</title><p>Since a gene-dosage imbalance of the <italic>Aph1b</italic> gene was the molecular-genetic basis of the APO-SUS/-UNSUS rat model <xref ref-type="bibr" rid="pone.0003662-Coolen1">&#x0005b;9&#x0005d;</xref> and the model was characterized by a disturbed endothelium-dependent vascular reactivity <xref ref-type="bibr" rid="pone.0003662-Riksen1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0003662-Smits1">&#x0005b;7&#x0005d;</xref>, we tested the hypothesis that a genetic variation in the <italic>APH1B</italic> gene may contribute to atherosclerosis susceptibility in humans. In a Dutch case-control cohort consisting of 780 patients with premature coronary atherosclerosis and 1414 controls, we found a higher prevalence of the <italic>APH1B</italic> Phe217Leu risk allele (G-allele) in the patients, albeit not statistically different (&#x003c7;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;2.09, <italic>df</italic>&#x0200a;&#x0003d;&#x0200a;1, p&#x0200a;&#x0003d;&#x0200a;0.15; OR&#x0200a;&#x0003d;&#x0200a;1.35; CI&#x0200a;&#x0003d;&#x0200a;0.90&#x02013;2.01). Intriguingly, after gender stratification, the difference was significant in the male population (&#x003c7;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;4.52, <italic>df</italic>&#x0200a;&#x0003d;&#x0200a;1, p&#x0200a;&#x0003d;&#x0200a;0.033; OR&#x0200a;&#x0003d;&#x0200a;1.63; CI&#x0200a;&#x0003d;&#x0200a;1.04&#x02013;2.58), whereas females were not significantly different (&#x003c7;<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;1.62, <italic>df</italic>&#x0200a;&#x0003d;&#x0200a;1, p&#x0200a;&#x0003d;&#x0200a;0.20; OR&#x0200a;&#x0003d;&#x0200a;0.50; CI&#x0200a;&#x0003d;&#x0200a;0.17&#x02013;1.48) (<xref ref-type="table" rid="pone-0003662-t001">Table 1</xref>). Power analysis showed that for the detection in the female subpopulation of a risk effect similar to that observed in the male subpopulation, the power was insufficient (92&#x00025; power for the total population; 81&#x00025; power for the male subpopulation and 38&#x00025; power for the female subpopulation, assuming a relative risk of 1.63, a disease allele frequency of 3.3&#x00025; and a disease prevalence of 5&#x00025;). All genotype distributions tested (cases and controls) fulfilled the Hardy-Weinberg criteria (data not shown).</p><table-wrap id="pone-0003662-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0003662.t001</object-id><label>Table 1</label><caption><title>Genotype and allele frequencies for the <italic>APH1B</italic> Phe217Leu variation in a Dutch case-control study on premature coronary atherosclerosis.</title></caption><graphic id="pone-0003662-t001-1" xlink:href="pone.0003662.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0003662-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N</td><td colspan="3" align="left" rowspan="1">Genotype Frequencies (&#x00025;)</td><td colspan="2" align="left" rowspan="1">Allele Frequencies (&#x00025;)</td><td align="left" rowspan="1" colspan="1"><italic>p</italic></td><td align="left" rowspan="1" colspan="1">OR</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">TG</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td colspan="9" align="left" rowspan="1"><bold>total</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">controls</td><td align="left" rowspan="1" colspan="1">1414</td><td align="left" rowspan="1" colspan="1">96.0</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">98.0</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">patients</td><td align="left" rowspan="1" colspan="1">780</td><td align="left" rowspan="1" colspan="1">94.6</td><td align="left" rowspan="1" colspan="1">5.4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">97.3</td><td align="left" rowspan="1" colspan="1">2.7</td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">1.35</td></tr><tr><td colspan="9" align="left" rowspan="1"><bold>males</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">controls</td><td align="left" rowspan="1" colspan="1">938</td><td align="left" rowspan="1" colspan="1">95.9</td><td align="left" rowspan="1" colspan="1">4.1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">98.0</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">patients</td><td align="left" rowspan="1" colspan="1">582</td><td align="left" rowspan="1" colspan="1">93.5</td><td align="left" rowspan="1" colspan="1">6.5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">96.7</td><td align="left" rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">0.033<sup>&#x0002a;</sup></td><td align="left" rowspan="1" colspan="1">1.63</td></tr><tr><td colspan="9" align="left" rowspan="1"><bold>females</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">controls</td><td align="left" rowspan="1" colspan="1">476</td><td align="left" rowspan="1" colspan="1">96.0</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">98.0</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">patients</td><td align="left" rowspan="1" colspan="1">198</td><td align="left" rowspan="1" colspan="1">98.0</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">99.0</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">0.50</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label/><p>Standard Chi-square tests were applied to evaluate the association with premature coronary atherosclerosis. OR&#x0200a;&#x0003d;&#x0200a;odds ratio; &#x0002a;<italic>p</italic>&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>Association of <italic>APH1B</italic> Leu217 with fibrinogen levels in premature coronary atherosclerosis</title><p>We then compared the association of the <italic>APH1B</italic> Leu217 allele with clinical parameters in the atherosclerosis patients, including the presence of risk factors (e.g. smoking behavior and occurrence of hypertension and diabetes mellitus), and the blood levels of lipid compounds (e.g. cholesterol, triglycerides, and low- and high-density lipoprotein cholesterol) (for a detailed overview of the parameters tested, see <xref ref-type="table" rid="pone-0003662-t002">Table 2</xref>). These parameters were not related to the <italic>APH1B</italic> Phe217Leu variation (<xref ref-type="table" rid="pone-0003662-t002">Table 2</xref>), except for a significant association (p&#x0200a;&#x0003d;&#x0200a;0.028) with the fibrinogen levels in patients containing or lacking the <italic>APH1B</italic> Leu217 allele. Patients without the Leu217 allele displayed fibrinogen levels of 322.8&#x000b1;80.55 gr/l (n&#x0200a;&#x0003d;&#x0200a;327, plus SD), whereas patients with the Leu217 allele had levels of 375.0&#x000b1;82.08 gr/l (n&#x0200a;&#x0003d;&#x0200a;12, plus SD) (<xref ref-type="table" rid="pone-0003662-t002">Table 2</xref>); due to low female patient numbers, gender stratification for fibrinogen levels was not possible. After Bonferroni adjustment for multiple comparisons, however, no statistically significant association of the fibrinogen levels with the Leu217 allele was detected (Bonferroni's adjustment requires a significance level of p&#x02264;0.00156).</p><table-wrap id="pone-0003662-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0003662.t002</object-id><label>Table 2</label><caption><title>Clinical and biochemical characteristics of the premature coronary atherosclerosis patients with and without the <italic>APH1B</italic> 217Leu allele.</title></caption><graphic id="pone-0003662-t002-2" xlink:href="pone.0003662.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0003662-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">without <italic>APH1B</italic> Leu217</td><td colspan="2" align="left" rowspan="1">with <italic>APH1B</italic> Leu217</td><td align="left" rowspan="1" colspan="1"><italic>p</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">values&#x000b1;SD</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">values&#x000b1;SD</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">43.3&#x000b1;5.3</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">42.9&#x000b1;5.3</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.60</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m2)</td><td align="left" rowspan="1" colspan="1">26.9&#x000b1;4.2</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">26.8&#x000b1;3.1</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1">Age first manisfestation of vascular event (years)</td><td align="left" rowspan="1" colspan="1">41.6&#x000b1;5.9</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">40.9&#x000b1;6.1</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">129.1&#x000b1;17.2</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">127.0&#x000b1;18.5</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">79.5&#x000b1;10.5</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">81.2&#x000b1;12.6</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol prior to medication (mmol/l)</td><td align="left" rowspan="1" colspan="1">6.3&#x000b1;1.9</td><td align="left" rowspan="1" colspan="1">286</td><td align="left" rowspan="1" colspan="1">6.6&#x000b1;1.4</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol prior to medication (mmol/l)</td><td align="left" rowspan="1" colspan="1">3.9&#x000b1;1.3</td><td align="left" rowspan="1" colspan="1">220</td><td align="left" rowspan="1" colspan="1">4.4&#x000b1;1.3</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol prior to medication (mmol/l)</td><td align="left" rowspan="1" colspan="1">1.1&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">231</td><td align="left" rowspan="1" colspan="1">1.0&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerids prior to medication (mmol/l)</td><td align="left" rowspan="1" colspan="1">1.8&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1">229</td><td align="left" rowspan="1" colspan="1">1.9&#x000b1;0.7</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol with medication (mmol/l)</td><td align="left" rowspan="1" colspan="1">5.0&#x000b1;1.5</td><td align="left" rowspan="1" colspan="1">738</td><td align="left" rowspan="1" colspan="1">4.9&#x000b1;1.7</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol with medication (mmol/l)</td><td align="left" rowspan="1" colspan="1">3.0&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1">730</td><td align="left" rowspan="1" colspan="1">3.1&#x000b1;1.8</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol with medication (mmol/l)</td><td align="left" rowspan="1" colspan="1">1.1&#x000b1;0.3</td><td align="left" rowspan="1" colspan="1">737</td><td align="left" rowspan="1" colspan="1">1.1&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerids with medication (mmol/l)</td><td align="left" rowspan="1" colspan="1">2.1&#x000b1;4.0</td><td align="left" rowspan="1" colspan="1">738</td><td align="left" rowspan="1" colspan="1">1.8&#x000b1;1.6</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Apo A1 lipoprotein (mmol/l)</td><td align="left" rowspan="1" colspan="1">1.3&#x000b1;0.3</td><td align="left" rowspan="1" colspan="1">495</td><td align="left" rowspan="1" colspan="1">1.2&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Apo B100 lipoprotein (mmol/l)</td><td align="left" rowspan="1" colspan="1">1.1&#x000b1;0.6</td><td align="left" rowspan="1" colspan="1">494</td><td align="left" rowspan="1" colspan="1">1.0&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Lipoprotein (a) (mg/l)</td><td align="left" rowspan="1" colspan="1">215.2&#x000b1;309.4</td><td align="left" rowspan="1" colspan="1">496</td><td align="left" rowspan="1" colspan="1">240.7&#x000b1;377.1</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood sedimentation rate (BSE) (mm/h)</td><td align="left" rowspan="1" colspan="1">10.4&#x000b1;11.3</td><td align="left" rowspan="1" colspan="1">345</td><td align="left" rowspan="1" colspan="1">9.4&#x000b1;5.2</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">Fibrinogen (gr/l)</td><td align="left" rowspan="1" colspan="1">322.8&#x000b1;80.5</td><td align="left" rowspan="1" colspan="1">327</td><td align="left" rowspan="1" colspan="1">375.0&#x000b1;82.1</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">0.028 &#x0002a;</td></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0003662-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x00025;</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">&#x00025;</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1"><italic>p</italic></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Acute myocardial infarction</td><td align="left" rowspan="1" colspan="1">73.34</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">69.05</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary angiography abnormal</td><td align="left" rowspan="1" colspan="1">98.23</td><td align="left" rowspan="1" colspan="1">621</td><td align="left" rowspan="1" colspan="1">97.14</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Percutaneous transluminal coronary angioplasty</td><td align="left" rowspan="1" colspan="1">66.98</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">80.95</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery bypass grafting</td><td align="left" rowspan="1" colspan="1">7.98</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">4.76</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Complaints claudication (&#x0003c;500 m walking distance)</td><td align="left" rowspan="1" colspan="1">11.77</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">7.14</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">Percutaneous transluminal angioplasty</td><td align="left" rowspan="1" colspan="1">7.58</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">7.14</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">Peripheral artery bypass grafting</td><td align="left" rowspan="1" colspan="1">2.84</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">Cerebro vascular accident</td><td align="left" rowspan="1" colspan="1">2.98</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">4.88</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking before the first event date</td><td align="left" rowspan="1" colspan="1">75.24</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">66.67</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Treated for hypertension</td><td align="left" rowspan="1" colspan="1">25.44</td><td align="left" rowspan="1" colspan="1">735</td><td align="left" rowspan="1" colspan="1">33.33</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Treated for diabetes mellitus</td><td align="left" rowspan="1" colspan="1">7.44</td><td align="left" rowspan="1" colspan="1">739</td><td align="left" rowspan="1" colspan="1">4.76</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypercholesterolemia treatment first degree relative</td><td align="left" rowspan="1" colspan="1">48.37</td><td align="left" rowspan="1" colspan="1">552</td><td align="left" rowspan="1" colspan="1">48.57</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension treatment first degree relative</td><td align="left" rowspan="1" colspan="1">45.71</td><td align="left" rowspan="1" colspan="1">617</td><td align="left" rowspan="1" colspan="1">47.37</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes treatment first degree relative</td><td align="left" rowspan="1" colspan="1">27.42</td><td align="left" rowspan="1" colspan="1">660</td><td align="left" rowspan="1" colspan="1">23.08</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">0.55</td></tr></tbody></table><table-wrap-foot><fn id="nt102"><label/><p>Values are given as mean levels&#x000b1;SD or as percentages. N, number of individuals tested; BMI, body mass index; LDL, low density lipoprotein; HDL, high density lipoprotein; Apo, apolipoprotein. &#x0002a;<italic>p</italic>&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c"><title>Evolutionary conservation of amino acid residue Phe217 within the APH1 family</title><p>The degree of conservation of an amino acid within a protein family is usually indicative of its importance for protein functioning. A multiple sequence alignment of members of the <italic>APH1</italic> family (<xref ref-type="fig" rid="pone-0003662-g001">Figure 1</xref>) showed that the Phe217 residue is conserved from plant, invertebrates, lower vertebrates, rodents and primates to man. The various APH1 proteins all contain at residue 217 either a phenylalanine (F) or the conservative change to tyrosine (Y). The Support Vector Machine (SVM) score (<ext-link ext-link-type="uri" xlink:href="http://www.SNPs3D.org">http://www.SNPs3D.org</ext-link>) <xref ref-type="bibr" rid="pone.0003662-Yue1">&#x0005b;16&#x0005d;</xref> of &#x02212;1.12 for Phe217Leu indicates a likely impact of this substitution on APH1B protein function.</p><fig id="pone-0003662-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0003662.g001</object-id><label>Figure 1</label><caption><title>Alignment of vertebrate and invertebrate amino acid sequences of the region within APH1 surrounding residue 217.</title><p>A black background indicates identical amino acid residues; a grey background indicates a conservative amino acid change. Abbreviations: Hs, <italic>Homo sapiens</italic>; Pt, <italic>Pan troglodytes</italic>; Rn, <italic>Rattus norvegicus</italic>; Mm, <italic>Mus musculus</italic>; Xt, <italic>Xenopus tropicalis</italic>; Dr, <italic>Danio rerio</italic>; Dm, <italic>Drosophila melanogaster</italic>; Ce, <italic>Caenorhabditis elegans</italic>; At, <italic>Arabidopsis thaliana</italic>. Sequences were aligned using Vector NTI (9.0) with default parameters.</p></caption><graphic xlink:href="pone.0003662.g001"/></fig></sec><sec id="s2d"><title>Functional analysis of the <italic>APH1B</italic> Phe217Leu polymorphism</title><p>We wondered whether the presence of a leucine instead of the conserved residue Phe217 of the APH1B protein would be of functional importance. <italic>Aph1abc<sup>&#x02212;/&#x02212;</sup></italic> mouse embryonic fibroblasts were stably transfected with human APH1B Phe217 or Leu217. &#x003b3;-Secretase activity was measured by quantifying the levels of different &#x003b3;-secretase substrates in cell culture extracts. We observed a 1.6-fold reduction (p&#x0003c;0.05, n&#x0200a;&#x0003d;&#x0200a;8) of &#x003b3;-secretase activity towards one of its substrates, syndecan-3 <xref ref-type="bibr" rid="pone.0003662-Schulz2">&#x0005b;17&#x0005d;</xref>, indicating a subtle influence on &#x003b3;-secretase cleavage activity. The cleavages of two other substrates, N-cadherin and APP, were slightly but not significantly changed (<xref ref-type="fig" rid="pone-0003662-g002">Figure 2</xref>). Thus, in a substrate-dependent manner the Phe217Leu substitution affected &#x003b3;-secretase cleavage activity.</p><fig id="pone-0003662-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0003662.g002</object-id><label>Figure 2</label><caption><title>&#x003b3;-Secretase cleavage activity of human wild-type APH1B (Phe217) and human mutant APH1B (Leu217) stably transfected into <italic>Aph1abc<sup>&#x02212;/&#x02212;</sup></italic> mouse embryonic fibroblast cells.</title><p>The levels of the C-terminal fragments (CTFs) of N-cadherin, APP and syndecan 3 were analysed in cells stably transfected with human APH1B Phe217 (WT) or human APH1B Leu217 (MUT). In the MUT cells, the CTF levels of N-cadherin and APP were slightly increased (1.1-fold and 1.2-fold, respectively), but the difference failed to reach significance. The levels of syndecan-3-CTF were significantly increased (1.6-fold; p&#x0200a;&#x0003d;&#x0200a;0.044), indicating a reduced &#x003b3;-secretase cleavage activity. Bars represent quantifications of CTF signals normalized to full-length protein levels in eight stably transfected cell lines with the average level in WT cell lines set to 100&#x00025;. &#x0002a;: <italic>p</italic>&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0003662.g002"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>In this study we show that the non-synonymous Phe217Leu polymorphism in the human <italic>APH1B</italic> gene is a male-specific risk factor for premature coronary atherosclerosis. The reduced &#x003b3;-secretase cleavage activity of Leu217 APH1B, albeit in a substrate-specific manner, suggests a functional relevance of this polymorphism. Functional consequences of reduced gene dosage of <italic>Aph1b</italic> were also observed in the APO-SUS/-UNSUS rat model <xref ref-type="bibr" rid="pone.0003662-Coolen1">&#x0005b;9&#x0005d;</xref>, an animal model with complex features, including an impaired vasorelaxation response to adrenergic stimuli <xref ref-type="bibr" rid="pone.0003662-Riksen1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0003662-Smits1">&#x0005b;7&#x0005d;</xref>, which increases the risk for the development of hypertension and vascular diseases. The gene-dosage imbalance of the <italic>Aph1b</italic> gene (three gene copies in APO-UNSUS rats and one or two gene copies in APO-SUS rats) segregated with differences in &#x003b3;-secretase cleavage activity and a number of other phenotypic characteristics <xref ref-type="bibr" rid="pone.0003662-Coolen1">&#x0005b;9&#x0005d;</xref>. We therefore speculate that a subtle effect on <italic>APH1B</italic> expression or function (copy number variation in rat or Phe217Leu variation in human, respectively) may affect &#x003b3;-secretase activity and signalling downstream of gamma-secretase cleavage and, consequently, give rise to vascular complications. Interestingly, the <italic>APH1B</italic> Phe217Leu polymorphism was recently found to be also associated with AD <xref ref-type="bibr" rid="pone.0003662-Poli1">&#x0005b;15&#x0005d;</xref>. AD pathogenesis is frequently characterized by a peripheral vascular disturbance and is often linked to other cholesterol/lipoprotein diseases, including atherosclerosis <xref ref-type="bibr" rid="pone.0003662-Casserly1">&#x0005b;18&#x0005d;</xref>. In addition, cerebral atherosclerosis has been found to be a strong contributory factor to sporadic AD pathogenesis <xref ref-type="bibr" rid="pone.0003662-Roher1">&#x0005b;19&#x0005d;</xref>. The <italic>APH1B</italic> Phe217Leu variation may thus play a dual role by affecting atherosclerosis as well as AD pathogenesis, suggesting that the two diseases have converged and that the &#x003b3;-secretase signalling pathway is a susceptibility pathway for vascular complications.</p><p>In line with the above supposition, a number of the &#x003b3;-secretase substrates have been implicated in vascular pathogenesis. <italic>LRP</italic>, which belongs to a gene family involved in mediating cellular uptake of cholesterol-rich lipoproteins (the low-density lipoprotein receptor (<italic>LDLR</italic>) gene family), is highly expressed in atherosclerotic lesions <xref ref-type="bibr" rid="pone.0003662-Luoma1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0003662-Hiltunen1">&#x0005b;21&#x0005d;</xref> and has been shown to represent a susceptibility gene for atherosclerosis <xref ref-type="bibr" rid="pone.0003662-Schulz1">&#x0005b;13&#x0005d;</xref>. The AD-associated &#x003b3;-secretase substrate APP may be involved in vascular pathogenesis as well, since it metabolises cholesterol <xref ref-type="bibr" rid="pone.0003662-Nelson1">&#x0005b;22&#x0005d;</xref>, physically interacts with LRP1 <xref ref-type="bibr" rid="pone.0003662-Rebeck1">&#x0005b;23&#x0005d;</xref>, and gives rise to the amyloid plaque constituents A&#x003b2;-40 and -42. Besides these well-studied substrates, the &#x003b3;-secretase substrates NOTCH3, colony-stimulating factor 1 (CSF1), CD44, neuregulin and ERBB4 may also be involved in the vascular complications in patients with the <italic>APH1B</italic> Phe217Leu variation. Mutations in <italic>NOTCH3</italic> may cause cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoecephelopathy (CADASIL), a syndrome characterized by systemic vascular smooth muscle cell (VSMC) degeneration <xref ref-type="bibr" rid="pone.0003662-Wang1">&#x0005b;24&#x0005d;</xref>. CSF1 can contribute to atherosclerosis development via fatty streak formation and progression to complex fibrous lesions <xref ref-type="bibr" rid="pone.0003662-Rajavashisth1">&#x0005b;25&#x0005d;</xref>, and CD44 may enhance atherosclerosis pathogenesis via reactive oxygen species <xref ref-type="bibr" rid="pone.0003662-Vendrov1">&#x0005b;26&#x0005d;</xref>, whereas neuregulin and ERBB4 are necessary for vascular growth and development <xref ref-type="bibr" rid="pone.0003662-Gassmann1">&#x0005b;27&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0003662-Meyer1">&#x0005b;29&#x0005d;</xref>.</p><p>Our results show that, remarkably, only male individuals with atherosclerosis seem to be associated with the <italic>APH1B</italic> Phe217Leu variation. This might indicate a role for hormones or the involvement of a Y-chromosome-linked modulation. Such a gender-specific association has been observed for other SNPs as well, like a male-specific association of the <italic>APOE2</italic> and <italic>APOE4</italic> alleles with cardiovascular disease <xref ref-type="bibr" rid="pone.0003662-Lahoz1">&#x0005b;30&#x0005d;</xref>. Thus, susceptibility to many common diseases may well be the result of complex interactions involving gender, genes and environmental factors. Following Bonferroni correction for multiple testing, no significant associations between the <italic>APH1B</italic> polymorphism and plasma lipoprotein parameters or other risk factors were observed in the atherosclerosis patients. More detailed studies will be necessary to establish the biochemical mechanisms underlying atherosclerosis in patients carrying the Phe217Leu polymorphism.</p><p>In the present study, association was only tested for premature coronary atherosclerosis, a disease with a substantial heritability <xref ref-type="bibr" rid="pone.0003662-Rissanen1">&#x0005b;31&#x0005d;</xref>. To investigate whether the Phe217Leu SNP constitutes a susceptibility factor for other vascular complications, it would be of interest to also test for association in elderly atherosclerotic patients and in patients with other vascular defects (e.g. myocardial infarction). No significant association of the <italic>APH1B</italic> chromosomal region with coronary artery disease, myocardial infarction or other related diseases has been found in recent genome-wide association studies (GWAS) <xref ref-type="bibr" rid="pone.0003662-ODonnell1">&#x0005b;32&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0003662-McPherson1">&#x0005b;35&#x0005d;</xref>. Thus, apart from the functional Phe217Leu polymorphism, the contribution of any additional genetic variant in the <italic>APH1B</italic> gene to the phenotype is expected to be small. Unfortunately, no results for the <italic>APH1B</italic> Phe217Leu polymorphism are available from the GWAS since this polymorphism was not represented on the arrays used in these studies. In addition, based on the data from the International HapMap-CEU project none of the SNPs tested in the GWAS is in near perfect proxy (r<sup>2</sup>&#x02265;0.8) to the Phe217Leu polymorphism. Therefore, the GWAS data do not provide any additional information concerning the functional <italic>APH1B</italic> Phe217Leu SNP.</p><p>In conclusion, our results suggest that the &#x003b3;-secretase pathway is a candidate pathway for premature coronary atherosclerosis and warrant further studies on genetic variations in this pathway in various diseases with vascular complications.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Subjects</title><p>We selected consecutive Dutch premature coronary atherosclerosis patients (n&#x0200a;&#x0003d;&#x0200a;780, age 43.3&#x000b1;5.3; 582 males, age 43.6&#x000b1;5.3 and 198 females, age 42.5&#x000b1;5.5) who qualified for inclusion after a myocardial infarction, surgical or percutaneous coronary revascularization, or a coronary angiogram with evidence of at least a 70&#x00025; stenosis in a major epicardial artery (Atherosclerosis Outpatient Clinic of the Academic Medical Center of the University of Amsterdam). The study was approved by the Medical Ethical Committee of the Academic Medical Center (Amsterdam, The Netherlands) and all patients gave written informed consent. The control subjects (n&#x0200a;&#x0003d;&#x0200a;1414, age 51.8&#x000b1;11.9; 938 males, age 53.7&#x000b1;10.9 and 476 females, age 48.2&#x000b1;12.9) were from the Sanquin Blood Bank. Volunteers were recruited at their blood donation session at one of the collection sites of the Sanquin Blood Bank covering the north west of the Netherlands. Therefore more than &#x0003e;95&#x00025; of these donors lived in the Dutch postal code area 1000&#x02013;4000. This area was chosen while the Amsterdam patient cohort geographically overlaps the region of the blood donor cohort serving as control donors.</p></sec><sec id="s4b"><title>Biochemical analysis</title><p>In the atherosclerosis patients, plasma cholesterol and triglycerides were determined with commercially available enzymatic methods (Boehringer Mannheim, FRG, No. 237574, and Sera-PAK, No. 6639, respectively). To determine high-density lipoprotein cholesterol, the polyethylene glycol 6000 precipitation method was used. Low-density lipoprotein cholesterol was calculated by the Friedewald formula.</p></sec><sec id="s4c"><title>APH1B genotyping</title><p>Following the isolation of genomic DNA, <italic>APH1B</italic> (MIM# 607630) Phe217Leu genotyping was performed via allele-specific PCR using primers specific for SNP rs1047552 (outer/general primers: forward: <named-content content-type="gene">5&#x02032;-TGCCTTCTAGGGTTACCATCTGA-3&#x02032;</named-content> and reverse: <named-content content-type="gene">5&#x02032;-AGTCGGCTTTACACTGTCCCA-3&#x02032;</named-content>. Inner/specific primers: forward specific for the &#x0201c;T-allele&#x0201d;: <named-content content-type="gene">5&#x02032;-AATAAACCTGGCGTCAGCATTT-3&#x02032;</named-content> and reverse specific for the &#x0201c;G-allele&#x0201d;: <named-content content-type="gene">5&#x02032;-GCCCATGAGCACCAGGATTATC-3&#x02032;</named-content>).</p></sec><sec id="s4d"><title>Generation of Aph1abc<sup>&#x02212;/&#x02212;</sup> mouse embryonic fibroblast (MEF) lines</title><p>Conditionally targeted (<italic>Aph1a</italic> and <italic>Aph1c</italic>) or classically targeted (<italic>Aph1b</italic>) mice were described before <xref ref-type="bibr" rid="pone.0003662-Serneels1">&#x0005b;36&#x0005d;</xref>. Animals carrying a null allele were obtained after breeding with transgenic mice expressing a <italic>Pgk</italic> driven Cre-recombinase. Mouse embryos were dissected at E8.5 from <italic>Aph1abc<sup>&#x0002b;/&#x02212;</sup></italic> crosses and genotype was determined by PCR analysis on yolk sacs. Mouse embryonic fibroblast (MEF) cultures were derived from dissociated <italic>Aph1abc<sup>&#x02212;/&#x02212;</sup></italic> mouse embryos <xref ref-type="bibr" rid="pone.0003662-Herreman1">&#x0005b;37&#x0005d;</xref>.</p></sec><sec id="s4e"><title>Generation of stable cell lines</title><p>The Phe217 to Leu217 mutation was made using the QuikChange II site-directed mutagenesis kit (Stratagene), using human wild-type APH1B cloned into pcDNA3.1 Zeo&#x0002b; (Invitrogen) as template. The primers used to introduce the mutation were: <named-content content-type="gene">5&#x02032;-CCTGGCGTCAGCATTGATAATCCTGGTGCTC-3&#x02032;</named-content> (forward); <named-content content-type="gene">5&#x02032;-GAGCACCAGGATTATCAATGCTGACGCCAGG-3&#x02032;</named-content> (reverse). Phe217 and Leu217 hAPH1B were recloned into pMSCVpuro&#x0002a; and cotransfected into HEK293 cells with helper plasmid pIK Ecopac for packaging into retroviruses. Retroviruses were harvested and snap frozen aliquots were stored at &#x02212;80&#x000b0;C until use. MEF <italic>Aph1abc<sup>&#x02212;/&#x02212;</sup></italic> cells were transduced with retrovirus for 24 hrs followed by puromycin selection in DMEM/F12 supplemented with 10&#x00025; FCS until stable lines were obtained.</p></sec><sec id="s4f"><title>Measurement of gamma-secretase activity towards different substrates</title><p>Stably transfected MEFs were seeded and grown to confluency. Cells were rinsed twice with ice-cold PBS and lysed in 1&#x00025; Triton, and postnuclear fractions were isolated by centrifugation at 10,000 g for 15 min at 4&#x000b0;C. Proteins were quantified using a standard Bradford assay (Pierce) and 10&#x02013;15 &#x000b5;g protein/lane was loaded on Bis-Tris SDS-PAGE gels (Invitrogen) and transferred to nitrocellulose membranes for Western blot detection for the indicated proteins. Gamma-secretase activity towards each substrate was expressed as the level of substrate C-terminal fragment (the direct gamma-secretase substrate) relative to levels of full-length protein. For densitometric quantification, the films were scanned using an Image Scanner (Amersham Pharmacia) and analyzed using ImageMaster.</p></sec><sec id="s4g"><title>Antibodies</title><p>APP was detected with C-terminal pAb B63.1 and syndecan 3 with C-terminal mAb 2E9. An antibody against the N-cadherin C-terminus (clone 32, BD Bioscience) was purchased.</p></sec><sec id="s4h"><title>Statistical analysis</title><p>Genotype frequencies were tested for the Hardy-Weinberg equilibrium. Differences between cases and controls were analysed by standard contingency table analysis using two-tailed &#x003c7;<sup>2</sup> test probabilities. Odds ratios (95&#x00025; confidence intervals (CI)) were calculated as an index of the association of the <italic>APH1B</italic> genotypes with premature atherosclerosis. Continuous and categorical biochemical and clinical variables were determined with the Student's t-test and &#x003c7;<sup>2</sup>-analysis, respectively. A p-value&#x0003c;0.05 was considered statistically significant (GraphPad Software Inc, San Diego, CA, USA). Though being conservative, Bonferonni correction was used to determine the significance of the biochemical and clinical variables. Power calculations were estimated using Quanto v1.2 <xref ref-type="bibr" rid="pone.0003662-Gauderman1">&#x0005b;38&#x0005d;</xref>.</p></sec></sec></body><back><ack><p>We thank Dr. Bart de Strooper (Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium) for helpful support, Dr. Kenji Shirotani and Dr. Christian Haass (Laboratory for Alzheimer's and Parkinson's Disease Research, Ludwig-Maximilians-University, Munich, Germany) for the human <italic>APH1B</italic> wild-type plasmid, Dr. Guido David (Department of Molecular &#x00026; Developmental Genetics, VIB, Leuven, Belgium) for the anti-Syndecan3 antibody 2E9 and Dr. Bruce Jenks (Department of Cellular Animal Physiology, Radboud University Nijmegen, The Netherlands) for critical reading of the manuscript.</p></ack><ref-list><title>References</title><ref id="pone.0003662-Horejsi1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horejsi</surname><given-names>B</given-names></name><name><surname>Ceska</surname><given-names>R</given-names></name></person-group><year>2000</year><article-title>Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis.</article-title><source>Physiol Res</source><volume>49</volume><issue>Suppl 1</issue><fpage>S63</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">10984073</pub-id></citation></ref><ref id="pone.0003662-Salazar1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salazar</surname><given-names>LA</given-names></name><name><surname>Hirata</surname><given-names>MH</given-names></name><name><surname>Giannini</surname><given-names>SD</given-names></name><name><surname>Forti</surname><given-names>N</given-names></name><name><surname>Diament</surname><given-names>J</given-names></name><etal/></person-group><year>2000</year><article-title>Seven DNA polymorphisms at the candidate genes of atherosclerosis in Brazilian women with angiographically documented coronary artery disease.</article-title><source>Clin Chim Acta</source><volume>300</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">10958870</pub-id></citation></ref><ref id="pone.0003662-Morita1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Taguchi</surname><given-names>J</given-names></name><name><surname>Kurihara</surname><given-names>H</given-names></name><name><surname>Kitaoka</surname><given-names>M</given-names></name><name><surname>Kaneda</surname><given-names>H</given-names></name><etal/></person-group><year>1997</year><article-title>&#x0005b;Gene Polymorphism of 5, 10-methylenetetrahydrofolate reductase as a coronary risk factor&#x0005d;.</article-title><source>J Cardiol</source><volume>29</volume><fpage>309</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">9211089</pub-id></citation></ref><ref id="pone.0003662-Cools1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cools</surname><given-names>AR</given-names></name><name><surname>Brachten</surname><given-names>R</given-names></name><name><surname>Heeren</surname><given-names>D</given-names></name><name><surname>Willemen</surname><given-names>A</given-names></name><name><surname>Ellenbroek</surname><given-names>B</given-names></name></person-group><year>1990</year><article-title>Search after neurobiological profile of individual-specific features of Wistar rats.</article-title><source>Brain Res Bull</source><volume>24</volume><fpage>49</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">2310946</pub-id></citation></ref><ref id="pone.0003662-Ellenbroek1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellenbroek</surname><given-names>BA</given-names></name><name><surname>Sluyter</surname><given-names>F</given-names></name><name><surname>Cools</surname><given-names>AR</given-names></name></person-group><year>2000</year><article-title>The role of genetic and early environmental factors in determining apomorphine susceptibility.</article-title><source>Psychopharmacology (Berl)</source><volume>148</volume><fpage>124</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">10663426</pub-id></citation></ref><ref id="pone.0003662-Riksen1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Ellenbroek</surname><given-names>B</given-names></name><name><surname>Cools</surname><given-names>AR</given-names></name><name><surname>Siero</surname><given-names>H</given-names></name><name><surname>Rongen</surname><given-names>GA</given-names></name><etal/></person-group><year>2003</year><article-title>Stress susceptibility as a determinant of endothelium-dependent vascular reactivity in rat mesenteric arteries.</article-title><source>J Cardiovasc Pharmacol</source><volume>41</volume><fpage>625</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">12658065</pub-id></citation></ref><ref id="pone.0003662-Smits1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smits</surname><given-names>BW</given-names></name><name><surname>Siero</surname><given-names>HL</given-names></name><name><surname>Ellenbroek</surname><given-names>BA</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Cools</surname><given-names>AR</given-names></name><etal/></person-group><year>2002</year><article-title>Stress susceptibility as a determinant of the response to adrenergic stimuli in mesenteric resistance arteries of the rat.</article-title><source>J Cardiovasc Pharmacol</source><volume>40</volume><fpage>678</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">12409976</pub-id></citation></ref><ref id="pone.0003662-Hadi1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hadi</surname><given-names>HA</given-names></name><name><surname>Carr</surname><given-names>CS</given-names></name><name><surname>Al Suwaidi</surname><given-names>J</given-names></name></person-group><year>2005</year><article-title>Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome.</article-title><source>Vasc Health Risk Manag</source><volume>1</volume><fpage>183</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">17319104</pub-id></citation></ref><ref id="pone.0003662-Coolen1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coolen</surname><given-names>MW</given-names></name><name><surname>Van Loo</surname><given-names>KM</given-names></name><name><surname>Van Bakel</surname><given-names>NN</given-names></name><name><surname>Pulford</surname><given-names>DJ</given-names></name><name><surname>Serneels</surname><given-names>L</given-names></name><etal/></person-group><year>2005</year><article-title>Gene dosage effect on gamma-secretase component Aph-1b in a rat model for neurodevelopmental disorders.</article-title><source>Neuron</source><volume>45</volume><fpage>497</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">15721236</pub-id></citation></ref><ref id="pone.0003662-Kopan1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kopan</surname><given-names>R</given-names></name><name><surname>Ilagan</surname><given-names>MX</given-names></name></person-group><year>2004</year><article-title>Gamma-secretase: proteasome of the membrane?</article-title><source>Nat Rev Mol Cell Biol</source><volume>5</volume><fpage>499</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">15173829</pub-id></citation></ref><ref id="pone.0003662-Koo1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>EH</given-names></name><name><surname>Kopan</surname><given-names>R</given-names></name></person-group><year>2004</year><article-title>Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration.</article-title><source>Nat Med</source><volume>10</volume><issue>Suppl</issue><fpage>S26</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15272268</pub-id></citation></ref><ref id="pone.0003662-Rubinsztein1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name></person-group><year>1999</year><article-title>Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis.</article-title><source>Dement Geriatr Cogn Disord</source><volume>10</volume><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">10325447</pub-id></citation></ref><ref id="pone.0003662-Schulz1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>S</given-names></name><name><surname>Schagdarsurengin</surname><given-names>U</given-names></name><name><surname>Greiser</surname><given-names>P</given-names></name><name><surname>Birkenmeier</surname><given-names>G</given-names></name><name><surname>Muller-Werdan</surname><given-names>U</given-names></name><etal/></person-group><year>2002</year><article-title>The LDL receptor-related protein (LRP1/A2MR) and coronary atherosclerosis&#x02013;novel genomic variants and functional consequences.</article-title><source>Hum Mutat</source><volume>20</volume><fpage>404</fpage><pub-id pub-id-type="pmid">12402342</pub-id></citation></ref><ref id="pone.0003662-Kang1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>DE</given-names></name><name><surname>Saitoh</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><etal/></person-group><year>1997</year><article-title>Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease.</article-title><source>Neurology</source><volume>49</volume><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">9222170</pub-id></citation></ref><ref id="pone.0003662-Poli1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poli</surname><given-names>M</given-names></name><name><surname>Gatta</surname><given-names>LB</given-names></name><name><surname>Lovati</surname><given-names>C</given-names></name><name><surname>Mariani</surname><given-names>C</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name><etal/></person-group><year>2008</year><article-title>Interaction between the APOE epsilon4 allele and the APH-1b c&#x0002b;651T&#x0003e;G SNP in Alzheimer's disease.</article-title><source>Neurobiol Aging</source><volume>29</volume><fpage>1494</fpage><lpage>1501</lpage><pub-id pub-id-type="pmid">17466415</pub-id></citation></ref><ref id="pone.0003662-Yue1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>P</given-names></name><name><surname>Melamud</surname><given-names>E</given-names></name><name><surname>Moult</surname><given-names>J</given-names></name></person-group><year>2006</year><article-title>SNPs3D: candidate gene and SNP selection for association studies.</article-title><source>BMC Bioinformatics</source><volume>7</volume><fpage>166</fpage><pub-id pub-id-type="pmid">16551372</pub-id></citation></ref><ref id="pone.0003662-Schulz2"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>JG</given-names></name><name><surname>Annaert</surname><given-names>W</given-names></name><name><surname>Vandekerckhove</surname><given-names>J</given-names></name><name><surname>Zimmermann</surname><given-names>P</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><etal/></person-group><year>2003</year><article-title>Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase-dependent and modulates cytosolic signaling.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>48651</fpage><lpage>48657</lpage><pub-id pub-id-type="pmid">14504279</pub-id></citation></ref><ref id="pone.0003662-Casserly1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casserly</surname><given-names>I</given-names></name><name><surname>Topol</surname><given-names>E</given-names></name></person-group><year>2004</year><article-title>Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins.</article-title><source>Lancet</source><volume>363</volume><fpage>1139</fpage><lpage>1146</lpage><pub-id pub-id-type="pmid">15064035</pub-id></citation></ref><ref id="pone.0003662-Roher1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roher</surname><given-names>AE</given-names></name><name><surname>Esh</surname><given-names>C</given-names></name><name><surname>Kokjohn</surname><given-names>TA</given-names></name><name><surname>Kalback</surname><given-names>W</given-names></name><name><surname>Luehrs</surname><given-names>DC</given-names></name><etal/></person-group><year>2003</year><article-title>Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>23</volume><fpage>2055</fpage><lpage>2062</lpage><pub-id pub-id-type="pmid">14512367</pub-id></citation></ref><ref id="pone.0003662-Luoma1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luoma</surname><given-names>J</given-names></name><name><surname>Hiltunen</surname><given-names>T</given-names></name><name><surname>Sarkioja</surname><given-names>T</given-names></name><name><surname>Moestrup</surname><given-names>SK</given-names></name><name><surname>Gliemann</surname><given-names>J</given-names></name><etal/></person-group><year>1994</year><article-title>Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions.</article-title><source>J Clin Invest</source><volume>93</volume><fpage>2014</fpage><lpage>2021</lpage><pub-id pub-id-type="pmid">8182133</pub-id></citation></ref><ref id="pone.0003662-Hiltunen1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hiltunen</surname><given-names>TP</given-names></name><name><surname>Luoma</surname><given-names>JS</given-names></name><name><surname>Nikkari</surname><given-names>T</given-names></name><name><surname>Yla-Herttuala</surname><given-names>S</given-names></name></person-group><year>1998</year><article-title>Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development.</article-title><source>Circulation</source><volume>97</volume><fpage>1079</fpage><lpage>1086</lpage><pub-id pub-id-type="pmid">9531255</pub-id></citation></ref><ref id="pone.0003662-Nelson1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>TJ</given-names></name><name><surname>Alkon</surname><given-names>DL</given-names></name></person-group><year>2005</year><article-title>Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide.</article-title><source>J Biol Chem</source><volume>280</volume><fpage>7377</fpage><lpage>7387</lpage><pub-id pub-id-type="pmid">15591071</pub-id></citation></ref><ref id="pone.0003662-Rebeck1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rebeck</surname><given-names>GW</given-names></name><name><surname>Moir</surname><given-names>RD</given-names></name><name><surname>Mui</surname><given-names>S</given-names></name><name><surname>Strickland</surname><given-names>DK</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name><etal/></person-group><year>2001</year><article-title>Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP.</article-title><source>Brain Res Mol Brain Res</source><volume>87</volume><fpage>238</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">11245926</pub-id></citation></ref><ref id="pone.0003662-Wang1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Baron</surname><given-names>M</given-names></name><name><surname>Trump</surname><given-names>D</given-names></name></person-group><year>2008</year><article-title>An overview of Notch3 function in vascular smooth muscle cells.</article-title><source>Prog Biophys Mol Biol</source><volume>96</volume><fpage>499</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">17854869</pub-id></citation></ref><ref id="pone.0003662-Rajavashisth1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajavashisth</surname><given-names>T</given-names></name><name><surname>Qiao</surname><given-names>JH</given-names></name><name><surname>Tripathi</surname><given-names>S</given-names></name><name><surname>Tripathi</surname><given-names>J</given-names></name><name><surname>Mishra</surname><given-names>N</given-names></name><etal/></person-group><year>1998</year><article-title>Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice.</article-title><source>J Clin Invest</source><volume>101</volume><fpage>2702</fpage><lpage>2710</lpage><pub-id pub-id-type="pmid">9637704</pub-id></citation></ref><ref id="pone.0003662-Vendrov1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vendrov</surname><given-names>AE</given-names></name><name><surname>Madamanchi</surname><given-names>NR</given-names></name><name><surname>Hakim</surname><given-names>ZS</given-names></name><name><surname>Rojas</surname><given-names>M</given-names></name><name><surname>Runge</surname><given-names>MS</given-names></name></person-group><year>2006</year><article-title>Thrombin and NAD(P)H oxidase-mediated regulation of CD44 and BMP4-Id pathway in VSMC, restenosis, and atherosclerosis.</article-title><source>Circ Res</source><volume>98</volume><fpage>1254</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">16601225</pub-id></citation></ref><ref id="pone.0003662-Gassmann1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gassmann</surname><given-names>M</given-names></name><name><surname>Casagranda</surname><given-names>F</given-names></name><name><surname>Orioli</surname><given-names>D</given-names></name><name><surname>Simon</surname><given-names>H</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><etal/></person-group><year>1995</year><article-title>Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor.</article-title><source>Nature</source><volume>378</volume><fpage>390</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">7477376</pub-id></citation></ref><ref id="pone.0003662-Kramer1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>R</given-names></name><name><surname>Bucay</surname><given-names>N</given-names></name><name><surname>Kane</surname><given-names>DJ</given-names></name><name><surname>Martin</surname><given-names>LE</given-names></name><name><surname>Tarpley</surname><given-names>JE</given-names></name><etal/></person-group><year>1996</year><article-title>Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development.</article-title><source>Proc Natl Acad Sci USA</source><volume>93</volume><fpage>4833</fpage><lpage>4838</lpage><pub-id pub-id-type="pmid">8643489</pub-id></citation></ref><ref id="pone.0003662-Meyer1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Birchmeier</surname><given-names>C</given-names></name></person-group><year>1995</year><article-title>Multiple essential functions of neuregulin in development.</article-title><source>Nature</source><volume>378</volume><fpage>386</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">7477375</pub-id></citation></ref><ref id="pone.0003662-Lahoz1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lahoz</surname><given-names>C</given-names></name><name><surname>Schaefer</surname><given-names>EJ</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><etal/></person-group><year>2001</year><article-title>Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study.</article-title><source>Atherosclerosis</source><volume>154</volume><fpage>529</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">11257253</pub-id></citation></ref><ref id="pone.0003662-Rissanen1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rissanen</surname><given-names>AM</given-names></name></person-group><year>1979</year><article-title>Familial occurrence of coronary heart disease: effect of age at diagnosis.</article-title><source>Am J Cardiol</source><volume>44</volume><fpage>60</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">453047</pub-id></citation></ref><ref id="pone.0003662-ODonnell1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>CJ</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>D'Agostino</surname><given-names>RB</given-names></name><name><surname>Fox</surname><given-names>CS</given-names></name><name><surname>Hoffmann</surname><given-names>U</given-names></name><etal/></person-group><year>2007</year><article-title>Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study.</article-title><source>BMC Med Genet</source><volume>8</volume><issue>Suppl 1</issue><fpage>S4</fpage><pub-id pub-id-type="pmid">17903303</pub-id></citation></ref><ref id="pone.0003662-Helgadottir1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Helgadottir</surname><given-names>A</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Manolescu</surname><given-names>A</given-names></name><name><surname>Gretarsdottir</surname><given-names>S</given-names></name><name><surname>Blondal</surname><given-names>T</given-names></name><etal/></person-group><year>2007</year><article-title>A common variant on chromosome 9p21 affects the risk of myocardial infarction.</article-title><source>Science</source><volume>316</volume><fpage>1491</fpage><lpage>1493</lpage><pub-id pub-id-type="pmid">17478679</pub-id></citation></ref><ref id="pone.0003662-Samani1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>Erdmann</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>AS</given-names></name><name><surname>Hengstenberg</surname><given-names>C</given-names></name><name><surname>Mangino</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Genomewide association analysis of coronary artery disease.</article-title><source>N Engl J Med</source><volume>357</volume><fpage>443</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">17634449</pub-id></citation></ref><ref id="pone.0003662-McPherson1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McPherson</surname><given-names>R</given-names></name><name><surname>Pertsemlidis</surname><given-names>A</given-names></name><name><surname>Kavaslar</surname><given-names>N</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><etal/></person-group><year>2007</year><article-title>A common allele on chromosome 9 associated with coronary heart disease.</article-title><source>Science</source><volume>316</volume><fpage>1488</fpage><lpage>1491</lpage><pub-id pub-id-type="pmid">17478681</pub-id></citation></ref><ref id="pone.0003662-Serneels1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Serneels</surname><given-names>L</given-names></name><name><surname>Dejaegere</surname><given-names>T</given-names></name><name><surname>Craessaerts</surname><given-names>K</given-names></name><name><surname>Horre</surname><given-names>K</given-names></name><name><surname>Jorissen</surname><given-names>E</given-names></name><etal/></person-group><year>2005</year><article-title>Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo.</article-title><source>Proc Natl Acad Sci U S A</source><volume>102</volume><fpage>1719</fpage><lpage>1724</lpage><pub-id pub-id-type="pmid">15665098</pub-id></citation></ref><ref id="pone.0003662-Herreman1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herreman</surname><given-names>A</given-names></name><name><surname>Van Gassen</surname><given-names>G</given-names></name><name><surname>Bentahir</surname><given-names>M</given-names></name><name><surname>Nyabi</surname><given-names>O</given-names></name><name><surname>Craessaerts</surname><given-names>K</given-names></name><etal/></person-group><year>2003</year><article-title>gamma-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation.</article-title><source>J Cell Sci</source><volume>116</volume><fpage>1127</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">12584255</pub-id></citation></ref><ref id="pone.0003662-Gauderman1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gauderman</surname><given-names>WJ</given-names></name></person-group><year>2002</year><article-title>Sample size requirements for association studies of gene-gene interaction.</article-title><source>Am J Epidemiol</source><volume>155</volume><fpage>478</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">11867360</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was performed within the framework of project T5-209 of the Dutch Top Institute Pharma.</p></fn></fn-group></back></article> 